Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 38Lymphoma, Non-Hodgkin 17Lymphoma 8Hodgkin Disease 8Neoplasms, Plasma Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Sezary Syndrome 1Recurrence 1Paraproteinemias 1Myeloproliferative Disorders 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Hairy Cell 1Congenital Abnormalities 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Dexamethasone 109pomalidomide 53Cyclophosphamide 52Bortezomib 42fludarabine phosphate 33Lenalidomide 33Peripheral Blood Stem Cell Transplantation 28carfilzomib 26Mycophenolic Acid 25daratumumab 24Calcium Dobesilate 24Cyclosporine 22Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Whole-Body Irradiation 18Melphalan 17Radiotherapy 15Filgrastim 15Methotrexate 14fludarabine 12Methylprednisolone 12elotuzumab 11Cord Blood Stem Cell Transplantation 11selinexor 10ixazomib 9Etoposide 8Thalidomide 7Prednisone 7Panobinostat 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × plerixafor × Plasma cell × Clear all
NCT00903968 2020-06-02

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Dana-Farber Cancer Institute

Phase 1/2 Completed
58 enrolled 13 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡